Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | TK2 | O00142 | 1/20 | 0.59 |
| ▸ | TYMS | P04818 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21316832 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL887786 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL5982137 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2922785 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL887635 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL13030268 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL887788 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL535679 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL15457036 | 0.90 | TK1 (0.75) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL12883747 | 0.90 | TK1 (0.75) | TK1CYP1A2CYP3A4TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260261-B | Preparation method of fluorescent dye modified deoxynucleoside solid phase carrier | 苏州诺维康生物科技有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-115260261-A | Preparation method of deoxynucleoside solid-phase carrier modified by fluorescent dye | 苏州诺维康生物科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260036577-A1 | SANDWICH ASSAYS IN DROPLETS | BIO-RAD LABORATORIES, INC. | 2026-02-05 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20250257391-A1 | ROLLING CIRCLE AMPLIFICATION COMPRISING CROSSLINKING AND DE-CROSSLINKING | 10X GENOMICS, INC. | 2025-08-14 | — | — | US | disclosed |
| US-12359197-B2 | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides | ETAGEN PHARMA, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-12292440-B2 | Sandwich assays in droplets | BIO-RAD LABORATORIES, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2025042899-A2 | METHODS FOR IDENTIFYING COMPOUNDS BINDING TO A TARGET MOLECULE USING MIRROR-IMAGING OF THE TARGET MOLECULE | X-CHEM, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-115260261-B | Preparation method of fluorescent dye modified deoxynucleoside solid phase carrier | 苏州诺维康生物科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20080227104-A1 | Replication; hybridization; kits | RIKEN (JP) | 2008-09-18 | — | — | US | disclosed |
| EP-1970453-A2 | Primer, primer set, and nucleic acid amplification method and mutation detection method using the same | Riken (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1956089-A1 | METHOD FOR DETECTING TARGET NUCLEIC ACID WITH SPECIFIC BASE SEQUENCE AND SET OF NUCLEIC ACIDS FOR DETECTION | Japan Science and Technology Agency (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20060142238-A1 | Chemical compounds | NuCana plc (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1646639-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | University College Cardiff Consultants, Ltd. (GB) | 2006-04-19 | — | — | EP | disclosed |
| US-20050147973-A1 | Immobilized probes | GE HEALTHCARE UK LIMITED (GB) | 2005-07-07 | — | — | US | disclosed |
| EP-1520038-A2 | DETECTION OF CIRCULARIZED IMMOBILIZED NUCLEIC ACID PROBES | Amersham Biosciences UK Limited (GB) | 2005-04-06 | — | — | EP | disclosed |
| WO-2005012327-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003083137-A2 | DETECTION OF CIRCULARIZED IMMOBILIZED NUCLEIC ACID PROBES | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | TK1 472/4885CYP1A2 4471/4885CYP3A4 3959/4885 |
| US-20080227104-A1 | Replication; hybridization; kits | PCNA, POLL, RNGTT | TK1 300/4885CYP1A2 4851/4885CYP3A4 4220/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | TK1 1713/4885CYP1A2 1193/4885CYP3A4 987/4885 |
| US-20060142238-A1 | Chemical compounds | NUDT1, DCK, PNP | TK1 10/4885CYP1A2 3861/4885CYP3A4 3837/4885 |
| US-20260036577-A1 | SANDWICH ASSAYS IN DROPLETS | DIS3, S100A4, CHMP4B | TK1 2552/4885CYP1A2 4327/4885CYP3A4 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.